VIP - IECBT patients
The population is composed of hematologic malignancy patients receiving or patients who previously received immune effector cell-based therapy (IECBT), aged 18 years and older, who intend to receive the COVID-19 vaccine or have received the COVID-19 vaccine at any time in the past.
The population is composed of hematologic malignancy patients receiving or patients who previously received immune effector cell-based therapy (IECBT), aged 18 years and older, who intend to receive the COVID-19 vaccine or have received the COVID-19 vaccine at any time in the past.
-
Minimum age
-
18
-
Newborns
-
-
Twins
-
-
Countries
-
-
Territory
-
Edmonton, Montreal, Ottawa, Toronto
-
Ethnic Origin
-
-
Health Status
-
Participants are diagnosed with hematologic malignancy.
Participants are excluded if they have chronic myelogenous leukemia, myeloproliferative neoplasm not on cytoreductive therapy, or any absolute contraindications to the COVID-19 vaccine.
-
Other Criteria
-
Participants are or were receiving immune effector cell-based therapy such as bi-specific T-cell engagers or chimeric antigen receptor T-cells. Therapy type must elligible for COVID-19 vaccination.
Participants are excluded if they received an autologous stem cell transplantation (autoSCT) or allogeneic hematopoietic stem cell transplantation (alloSCT) treatment for non-hematologic malignancy diseases.
-
Sources of recruitment
-
-
Specific Population
-
-
Supplementary Information
-
Participants are recruited in hematology clinics from one of twelve participating hospitals around Canada.
-
Number of Participants
-
54
-
Number of Participants with Biological Samples
-
54
-
Supplementary Information about selection criteria
-
Participants are recruited in hematology clinics from one of twelve participating hospitals around Canada.